Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients. An ex vivo human study

Thrombosis and Haemostasis

Volumn 95, Issue 3, 2006, Pages 441-446

  Lev, Eli I ^a   Patel, Rajnikant ^a,b   Karim, Azim ^a   Kleiman, Amanda ^a   Badimon, Juan J ^c   Kleiman, Neal S ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet drugs; Antithrombin; Diabetes metabolic disorders; Direct antithrombin agents; Platelet pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PADGEM PROTEIN;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ELECTIVE SURGERY; EX VIVO STUDY; FEMALE; FIBRIN DEPOSITION; FLOW KINETICS; HIGH RISK PATIENT; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHEAR FLOW; SWINE; THROMBOCYTE; THROMBOGENESIS; THROMBOGENICITY; TUNICA MEDIA;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; THROMBOPLASTIN; THROMBOSIS;

EID: 33645552143     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-10-0700     Document Type: Article

References (39)

1. Elezi S, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-73.
2. Labinaz M, et al; ESPRIT Investigators. Comparison of one-year outcomes following coronary artery stenting in diabetic versus non-diabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin therapy [ESPRIT] trial). Am J Cardiol. 2002; 90: 585-90.
3. Abizaid A, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-9.
4. Tschoepe D. The activated megakaryocyte-platelet system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21: 152-60.
5. Keating FK, et al. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol 2004; 94: 725-8.
6. Yan Y, Phillips DR. Aspirin response and failure in diabetic patients with cardiovascular disease. Curr Opin Pharmacol 2005; 5: 190-7.
7. Giesen PL, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
8. Sambola A, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-7.
9. Bhatt DL, et al. Abciximab reduces mortality in diabetics following percutaneous intervention. J Am Coll Cardiol 2000; 35: 922-8.
10. Roffi M, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.
11. Kleiman NS, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence of a complex interaction in a multicenter trial. EPILOG investigators. Circulation 1998; 97: 1912-20.
12. Lincoff AM, et al; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292: 696-703.
13. Gurm HS, et al. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol 2005; 45: 1932-8.
14. Lincoff AM, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
15. Batchelor WB, et al. Randomized comparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106: 1470-6.
16. Lev EI, et al. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. J Am Coll Cardiol 2001; 37: 847-55.
17. Lev EI, et al. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. J Am Coll Cardiol 2004; 43: 966-71.
18. Dangas G, et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol 1998; 18: 1342-9.
19. Kleiman NS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/ IIIa antagonist eptifibatide. Am Heart J 2002; 143: 585-93.
20. Wittkowsky AK. The role of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy 2002; 22: 97S-104S.
21. Aggarwal A, et al. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 2002; 13: 161-5.
22. Keating FK, et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005; 16: 401-5.
23. Polgar J, et al. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005; 3: 1590-6.
24. Falati S, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.
25. Del Conde I, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-11.
26. Fernandez-Ortiz A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-9.
27. Badimon L, et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-18.
28. Mailhac A, et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: Relative contribution of fibrin(ogen) and platelets. Circulation 1994; 90: 988-96.
29. Toschi V, et al. Tissue factor modulates the thrombogenicity of atherosclerotic plaques. Circulation 1997; 95: 594-9.
30. Tschoepe D, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433-8.
31. Keating FK, et al. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes. Thromb Res 2004; 113: 27-34.
32. Swords NA, Mann KG. The assembly of the prothrombinase complex on adherent platelets. Arterioscler Thromb 1993; 13: 1602-12.
33. Hayes R, et al. Antithrombotic effects of abciximab. Am J Cardiol 2000; 85: 1167-72.
34. Hamelink JK, et al. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. J Vase Surg 1995; 21: 492-8.
35. Coppinger JA, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104.
36. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106:V275-84.
37. Steiner S, et al. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003; 23: 1697-702.
38. Kopp CW, et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke 2003; 34: 2560-7.
39. Shimbo D, et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-8.